Literature DB >> 18219450

Effect of Equiguard in treating patients with Shen-yang deficiency syndrome.

Pei-hua Xiong1, Ling Zhang, Shou-fu Tian, Mei-hua Gu, Ai-ping Chen.   

Abstract

OBJECTIVE: To observe the therapeutic effect of Equiguard in old patients with Shen-yang deficiency syndrome (SYDS).
METHODS: Twenty old patients with diagnosis matching the criteria of SYDS selected from out-patients were administered with Equiguard capsule 3 times per day, 0.70 g each time for 3 successive months. The changes in general condition, peripheral blood picture, function of the liver and kidney, and sex hormones before and after treatment were observed. The changes in the American Urinary Surgery Association (AUA) score of prostatism, urosis and residue urine in the urinary bladder were also estimated.
RESULTS: After the 3-month treatment, no significant change was found in the patients' general condition, peripheral blood picture, liver and kidney function and sex hormones, while the symptoms of prostatism and urosis were markedly improved (P<0.01), and the volume of residue urine in the urinary bladder was obviously reduced.
CONCLUSION: Equiguard shows a significant therapeutic effect in treating old patients with SYDS, which could effectively improve the symptoms of prostatism and urosis in patients and is highly safe.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18219450     DOI: 10.1007/s11655-007-9007-1

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  2 in total

1.  Analysis of gene expression and functional changes of adrenal gland in a rat model of kidney yang deficiency syndrome treated with Sini decoction.

Authors:  Nong Tang; Lihong Liu; Hua Qiu; Wei Shi; Dewen Mao
Journal:  Exp Ther Med       Date:  2018-07-25       Impact factor: 2.447

2.  Secretory IgA in Mucosa of Pharynx and Larynx Plays an Important Role against Influenza A Virus Infection in Kidney Yang Deficiency Syndrome Model.

Authors:  Shaozhe Zhao; Lei Yuan; Yi Li; Longchan Liu; Zixin Luo; Qingtao Lv; Rong Rong; Yong Yang
Journal:  Evid Based Complement Alternat Med       Date:  2020-03-29       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.